title: What challenges remain in chronic myeloid leukemia research?
authors.forename: Angelo M
authors.initials: AM
authors.lastname: Carella
authors.forename: Susan
authors.initials: S
authors.lastname: Branford
authors.forename: Michael
authors.initials: M
authors.lastname: Deininger
authors.forename: Francois X
authors.initials: FX
authors.lastname: Mahon
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Anna
authors.initials: A
authors.lastname: Eiring
authors.forename: Jamshid
authors.initials: J
authors.lastname: Khorashad
authors.forename: Thomas
authors.initials: T
authors.lastname: O'Hare
authors.forename: John M
authors.initials: JM
authors.lastname: Goldman
mesh_terms: D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000276:immunology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D057170:Translational Research, Biomedical / Q000639:trends
chemical_list: C581634:BCR-ABL1 fusion protein, human; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib
references.citation: Haematologica. 2011 Dec;96(12):1737-9
references.pmid: 22147770
references.citation: J Clin Invest. 2007 Sep;117(9):2562-9
references.pmid: 17710227
references.citation: Sci Transl Med. 2013 Mar 13;5(176):176ra33
references.pmid: 23486779
references.citation: Blood. 2011 Mar 24;117(12):3353-62
references.pmid: 21278353
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1674-83
references.pmid: 21307148
references.citation: J Natl Compr Canc Netw. 2012 Oct 1;10 Suppl 3:S1-S13
references.pmid: 23055247
references.citation: J Clin Invest. 2009 May;119(5):1109-23
references.pmid: 19363292
references.citation: N Engl J Med. 2012 Nov 29;367(22):2148-9
references.pmid: 23190226
references.citation: Blood. 2007 Jan 1;109(1):58-60
references.pmid: 16973963
references.citation: Blood. 2012 Mar 8;119(10):2234-8
references.pmid: 22210874
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Leuk Res. 2012 Jun;36(6):689-93
references.pmid: 22398220
references.citation: Cancer Cell. 2009 Nov 6;16(5):401-12
references.pmid: 19878872
references.citation: N Engl J Med. 2012 Nov 29;367(22):2075-88
references.pmid: 23190221
references.citation: Lancet Oncol. 2011 Sep;12(9):841-51
references.pmid: 21856226
references.citation: Nature. 2005 Jun 30;435(7046):1267-70
references.pmid: 15988530
references.citation: Blood. 2012 Jul 12;120(2):291-4
references.pmid: 22645182
references.citation: Clin Chem. 2007 Sep;53(9):1593-600
references.pmid: 17660274
references.citation: Blood. 2007 Mar 15;109(6):2303-9
references.pmid: 17138817
references.citation: Haematologica. 2012 Jun;97(6):903-6
references.pmid: 22180435
references.citation: J Clin Oncol. 2012 Jan 20;30(3):232-8
references.pmid: 22067393
references.citation: Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700
references.pmid: 19433805
references.citation: Blood. 2008 Dec 1;112(12):4437-44
references.pmid: 18716134
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:115-21
references.pmid: 23233569
references.citation: Leuk Lymphoma. 2013 Jan;54(1):198-201
references.pmid: 22656271
references.citation: Semin Hematol. 2010 Oct;47(4):312-8
references.pmid: 20875547
references.citation: Blood. 2009 Dec 3;114(24):4944-53
references.pmid: 19779040
references.citation: Lancet Oncol. 2010 Nov;11(11):1029-35
references.pmid: 20965785
references.citation: Blood. 2012 Feb 2;119(5):1123-9
references.pmid: 22160483
references.citation: Haematologica. 2011 May;96(5):664-71
references.pmid: 21330326
references.citation: Leukemia. 2010 Oct;24(10):1719-24
references.pmid: 20811403
references.citation: Leuk Lymphoma. 2012 Jul;53(7):1409-11
references.pmid: 22233113
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4250-9
references.pmid: 21990409
references.citation: N Engl J Med. 2010 Jun 17;362(24):2251-9
references.pmid: 20525993
references.citation: Curr Hematol Malig Rep. 2010 Apr;5(2):81-7
references.pmid: 20425400
references.citation: J Clin Oncol. 2009 Sep 1;27(25):4204-10
references.pmid: 19652056
references.citation: Nat Rev Cancer. 2012 Jul 24;12(8):513-26
references.pmid: 22825216
references.citation: N Engl J Med. 2010 Jun 17;362(24):2260-70
references.pmid: 20525995
references.citation: J Clin Oncol. 2012 Dec 10;30(35):4323-9
references.pmid: 23109697
references.citation: Eur J Haematol. 2010 Oct;85(4):358-60
references.pmid: 20633041
references.citation: Leukemia. 2012 May;26(5):1140-3
references.pmid: 22094585
references.citation: Leuk Res. 2012 Jun;36(6):756-63
references.pmid: 22209738
references.citation: Blood. 2002 Jan 1;99(1):319-25
references.pmid: 11756187
references.citation: Blood. 2009 Dec 3;114(24):4933-8
references.pmid: 19822896
references.citation: Leukemia. 2012 Sep;26(9):2096-102
references.pmid: 22446502